Akorn — Merger or Acquisition (May 2014)
9 slides from Akorn's merger presentation, May 12, 2014
Slide 1: VersaPharm Acquisition Announcement
Akorn, Inc. Nasdaq: AKRX May 12, 2014 VersaPharm Acquisition Announcement
Slide 2: Disclaimer
Disclaimer This presentation includes certain forward-looking statements regarding our views with respect to our business and our expected performance for future periods. These statements are intended as “forward-looking statements” under the Private Securities Litigation Reform Act of 1995.Actual r
Slide 3: Transaction strategic opportunity
Transaction strategic opportunity Entry into Dermatology & Further Product Diversification Establishes Akorn in the generic dermatology therapeutic category, given VersaPharm’s pipeline focus on topical productsAddition of over 20 marketed products Bolt on to Hi-Tech Acquisition Ease of Integration
Slide 4: Key transaction terms
Key transaction terms Purchase price $440 million Cash / share mix All cash; debt financed Funding mix Fully-committed financing from JPMorgan Chase Bank, N.A. Accretion Immediately accretive; $0.10 to $0.12 in full year earnings per share(excluding new pipeline launches, deal amortization and acqui
Slide 5: Akorn's proven acquisition strategy
MANUFACTURING CAPACITY LEVERAGE INFRASTRUCTURE FOCUS ON OPHTHALMOLOGY EXPAND NICHE PORTFOLIO ACCESS TO OTHER GEOGRAPHIES Akorn’s Proven acquisition strategy 2011 2012 2013 2014 Acquisition strategy is expected to contribute approximately $500 million in 2015 revenues Brand portfolio Branded Ophthalm
Slide 6: Overview of VersaPharm
Overview of Versapharm Overview % of 2013 revenue By therapeutic area Over 20 generic pharmaceutical products marketed within the US and its territoriesTotal of 45 employees in 3 locationsPortfolio covers niche therapeutic categories and product formatsOperates in markets which maintain a stable com
Slide 7: Enhanced R&D Capabilities and pipeline
Enhanced R&D Capabilities and pipeline Pipeline stats Overview VersaPharm has built a robust pipeline of over 20 products, including 11 ANDAs filed with the FDAStaff of 24 professionals based at the R&D center in Warminster, PAMajority of the 11 filed products can be manufactured at Hi-Tech Ability
Slide 8: Acquisition summary
Acquisition summary Highly strategic fit with Akorn’s focus on niche dosage formsIncreases presence in the highly attractive niche dermatology market Robust pipeline of over 20 products, including 11 ANDAs filed with the FDA, with an addressable IMS market value of over $700 millionExpertise in deve
Slide 9: CAKGRN
CAKGRN a @ ADVANCING THE NEW VISION SS